About US
Contact us
-
Bayer invests in U.S. growth to get it through its big transitionsPlenty ofBayer's peers are focusing their expansion efforts outside the U.S., on emerging markets with more growth potential. But not the German pharma. Instead, it's working to boost its presence an2016/4/5
-
Roche softens tone with U.K., says it is willing to try pay-for-performance pricingSince name-calling didn't get Roche ($RHHBY) the results it wanted with U.K. drug price watchdogs, executives are trying a new tactic: conciliation. The drugmaker has indicated it is open to price neg2016/4/5
-
Will SCOTUS take up Sandoz' pivotal biosim case? New briefs call on court to weigh inBiosimilars advocates are lining up behindSandozto persuade the U.S. Supreme Court to take up its case against Amgen ($AMGN). The closely watched legal tussle, over Sandoz's biosim copy Amgen's blockb2016/4/1
-
Label surprise boosts Jazz as it preps Defitelio rolloutIt's been a long road to FDA approval for Jazz Pharmaceuticals' ($JAZZ) Defitelio. But the Irish biotech is finally ready to launch the product--and a surprise on the product's label may help make tha2016/4/1
-
Bayer and Regeneron to develop combination therapy to treat eye diseasesBayer and Regeneron Pharmaceuticals have jointly developed a combination therapy for the treatment of eye diseases. Through the collaboration, Regeneron will combine its angiopoietin2 (Ang2) antibody2016/3/31
-
Sun Pharma to sell AstraZeneca's Type 2 diabetes medicine in IndiaSun Pharmaceutical Industries has entered a partnership with AstraZeneca to sell the latter's Type 2 diabetes (T2D) medicine, dapagliflozin, in India. Both firms have signed a distribution agreement.2016/3/31
-
Shire scores a patent victory for Lialda, but Bass-spurred PTO review loomsShire($SHPG) has scored a victory in its quest to protect its patent on ulcerative colitis med Lialda. Tuesday, it said the U.S. District Court for Southern Florida had upheld Lialda's IP shield, dete2016/3/30
-
In surprise decision, FDA blocks crucial cognitive claim for Takeda's BrintellixTheFDAdoesn't have to follow the advice of its expert review panels, but it usually does. That's a standard line in stories about advisory committee votes. Unfortunately forLundbeckandTakeda, their ne2016/3/30
-
Sanofi, Regeneron rack up some cost-savings data for their PCSK9 contender PraluentIt's not the cardiovascular outcomes data doctors and payers are waiting for, but it's outcomes data nonetheless. Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 contender Praluent helped patients with a2016/3/29
-
Merck's $200M damages in Gilead hep C case falls far short of expectationsMerck & Co. won ahepatitis Cpatent fight with Gilead Sciences last week, but if the jury's first damages award is any indication, the score could be much smaller than the $3 billion analysts had p2016/3/29